Sarepta Therapeutics (NASDAQ:SRPT) Earns Sell Rating from HC Wainwright

Sarepta Therapeutics (NASDAQ:SRPT)‘s stock had its “sell” rating reaffirmed by stock analysts at HC Wainwright in a note issued to investors on Monday,Benzinga reports. They currently have a $5.00 price objective on the biotechnology company’s stock. HC Wainwright’s price objective would suggest a potential downside of 70.17% from the stock’s current price.

SRPT has been the subject of several other research reports. Royal Bank Of Canada increased their target price on shares of Sarepta Therapeutics from $16.00 to $18.00 and gave the company a “sector perform” rating in a report on Thursday, January 8th. Wall Street Zen raised shares of Sarepta Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday. Barclays assumed coverage on shares of Sarepta Therapeutics in a research report on Wednesday, January 28th. They set an “equal weight” rating and a $20.00 target price on the stock. Mizuho raised Sarepta Therapeutics from a “neutral” rating to an “outperform” rating and upped their target price for the company from $19.00 to $26.00 in a report on Wednesday, November 5th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Sarepta Therapeutics in a research report on Monday, December 29th. Nine investment analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and six have issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $32.16.

Sarepta Therapeutics Stock Performance

Shares of Sarepta Therapeutics stock opened at $16.76 on Monday. Sarepta Therapeutics has a 52 week low of $10.41 and a 52 week high of $108.48. The company has a quick ratio of 1.48, a current ratio of 2.32 and a debt-to-equity ratio of 0.73. The business has a 50 day moving average price of $20.43 and a 200-day moving average price of $20.22. The company has a market cap of $1.76 billion, a PE ratio of -1.99, a price-to-earnings-growth ratio of 0.27 and a beta of 0.42.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported ($3.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.87) by ($2.71). Sarepta Therapeutics had a negative return on equity of 50.74% and a negative net margin of 38.34%.The company had revenue of $442.93 million for the quarter, compared to the consensus estimate of $390.95 million. During the same quarter last year, the company posted $1.90 EPS. The company’s quarterly revenue was down 32.7% compared to the same quarter last year. Equities analysts anticipate that Sarepta Therapeutics will post 2.67 earnings per share for the current fiscal year.

Insider Transactions at Sarepta Therapeutics

In other Sarepta Therapeutics news, COO Ian Michael Estepan sold 13,187 shares of the business’s stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $22.31, for a total value of $294,201.97. Following the sale, the chief operating officer directly owned 193,300 shares in the company, valued at $4,312,523. The trade was a 6.39% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 7.60% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Sarepta Therapeutics

Several large investors have recently added to or reduced their stakes in the company. AQR Capital Management LLC raised its stake in Sarepta Therapeutics by 454.6% in the 4th quarter. AQR Capital Management LLC now owns 7,796,535 shares of the biotechnology company’s stock valued at $167,781,000 after acquiring an additional 6,390,860 shares during the period. Vanguard Group Inc. increased its stake in shares of Sarepta Therapeutics by 18.1% in the third quarter. Vanguard Group Inc. now owns 10,817,446 shares of the biotechnology company’s stock worth $208,452,000 after purchasing an additional 1,657,267 shares in the last quarter. First Trust Advisors LP raised its position in shares of Sarepta Therapeutics by 209.1% in the third quarter. First Trust Advisors LP now owns 1,939,781 shares of the biotechnology company’s stock valued at $37,380,000 after purchasing an additional 1,312,220 shares during the period. Connor Clark & Lunn Investment Management Ltd. lifted its stake in shares of Sarepta Therapeutics by 183.5% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,745,051 shares of the biotechnology company’s stock valued at $33,627,000 after buying an additional 1,129,610 shares in the last quarter. Finally, Erste Asset Management GmbH boosted its holdings in Sarepta Therapeutics by 65.7% in the 3rd quarter. Erste Asset Management GmbH now owns 2,685,945 shares of the biotechnology company’s stock worth $50,588,000 after buying an additional 1,064,530 shares during the period. Hedge funds and other institutional investors own 86.68% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.